- Recent Coverage -

• ARPA-H is investing a billion dollars to encourage cutting-edge research for Alzheimer's, supporting bold ideas to pursue and drive new biomedical breakthroughs
• The Department of Health and Human Services is investing in research and technology to help keep Alzheimer's patients in their homes longer, train caregivers to support them, and educate Americans about Alzheimer's early warning signs – all of which MetAlert provides products and solutions for
• The Alzheimer’s Disease diagnostic and therapeutic market is expected to reach an estimated $9.6 billion by 2027

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, has announced that Canadian distributor Red Dot Alerts has launched the new award-winning 4G GPS SmartSole – a wearable medical monitoring device integrated into the orthotic insole allowing for discreet tracking and remote monitoring for those with Alzheimer's, dementia, and autism (https://ibn.fm/NSPZ4).

Cybin Inc.
(NYSE American: CYBN)
(NEO: CYBN)

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company focused on progressing psychedelics to therapeutics, offering a new standard of care for mental health disorders and improving patient outcomes. The company is led by a team of leading scientific and industry experts with deep roots in biotech, psychedelics, and mental health, to translate top-tier science into potential best-in-class therapeutics.

Cybin takes a holistic approach to psychedelic therapeutics that encompasses three pillars: drug discovery, drug delivery, and innovative treatment. This ‘bench to bedside’ approach enables Cybin to translate novel research into potential treatments for multiple mental health conditions, including depression, anxiety, and psychiatric disorders.

Investment Considerations

• Cybin Inc. currently has three molecules in development with four sponsored clinical trials planned for 2022 and a preclinical pipeline of 50+ novel assets.
• The company’s management team is composed of leaders with experience in various aspects of the pharmaceutical and innovative therapeutics market and is further supported by external partnerships with world-class scientists and CROs validating its R&D approach.
• Recent studies have shown promising effects on the use of psychedelic therapies for treating mental health disorders.
• The company has established a strong IP portfolio with patent applications in 150+ countries supported by a novel approach to developing traditional psychedelics into new chemical entities.
• Cybin’s therapeutic advances are catering to a global market of over 900 million people affected by mental health conditions, with an initial focus on major depressive disorder, alcohol use disorder and anxiety.
• The U.S. psychedelic therapies market is expected to expand significantly, reaching $6.9 billion by 2027, as the prevalence of mental conditions continues to increase.
• Cybin has raised over C$120 million to date; it is well-funded to progress clinical trials, M&A, and IP strategies.

- Recent Coverage -

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place Dec. 4-7, 2022, in Phoenix, Arizona. According to the update, the data, including new pharmacokinetics (“PK”) findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder (“MDD”). “These new findings demonstrate the unique PK properties of CYB003 compared with classical psilocybin and further supports our ongoing first-in-human phase 1/2a clinical trial evaluating CYB003 for the treatment of MDD,” said Cybin’s Chief Medical Officer Amir Inamdar, MBBS, DNB (Psych), MFPM. “We were honored to present our data at ACNP amongst leading scientists and academics in neuropsychopharmacology.”